Biotech Stocks Reviews
- FDA Under Enormous Pressure To Approve Fennec’s STS Drug Under Wide Label Following Testimony At Little-Known Patient Advocacy Event on September 13
Fri, Sep 14
For the first time since PropThink launched in late 2012, we travelled to a Patient Advocacy Meeting in · more » - Low Data Hurdle Makes Bellus Attractive Ahead of Q4 Catalyst
Sat, Aug 11
In December, Bellus Health (BLUSF:OTC) (BLU:TSX) will report Phase 1 data for their chronic cough · more » - Selecta’s Highly Anticipated Phase 2 Data Expected in October
Wed, Aug 8
Selecta released Q2 2018 results and announced updates regarding their Phase 2 SEL-212 5+0 dosing and · more » - Early EMA Discussions Suggesting Wide Label Approval for Fennec
Fri, Aug 3
The pediatric committee at the European Medicines Agency (EMA) held discussions last week on · more » - We’re Not Fans of GBT Moving Goal Posts After Phase 3 Data
Mon, Jul 2
Our original thesis was that GBT would show a clear improvement in at least 1 of 2 secondary events (in · more » - GBT Phase 3 – Part A Data Was Promising, But Vague
Wed, Jun 27
GBT announced their highly anticipated Phase 3 Part A data this morning and a lot was left to be · more » - Fennec Risk to Reward Remains Compelling with Full Data Set
Thu, Jun 21
Fennec (FENC) announced that their Phase 3 results, initially released back in October 2017 (read · more » - Selecta Remains on Track To Report Superior Data to Standard of Care
Fri, Jun 15
Selecta announced updated data on their 3+2 dosing for Phase 2 this morning. This data is not all that · more » - GBT’s Adolescent Data Does Not Suggest Phase 3 HOPE Will Be Negative
Fri, Jun 15
GBT released their EHA poster for sickle cell disease adolescent patients this morning. The stock is · more »